Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
PCI Biotech to present Phase I dose escalation results at ESMO | ||
By: Nasdaq / GlobeNewswire - 19 Oct 2018 | Back to overview list |
|
Oslo, Norway, 19 October 2018 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company will present results from the Phase I dose escalation study in perihilar cholangiocarcinoma (extrahepatic bile duct cancer) at the ESMO 2018 Congress in Munich, Germany (19 – 23 October 2018). One of the key investigators in the trial, Prof. Jörg Trojan, will present the poster during the poster display session Sunday 21 October, 12.45 – 13:45 CET in Hall A3 (presentation number 760P). Contact information: About PCI Biotech Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a clinical Phase I/II study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For further information, please visit: www.pcibiotech.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
|
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |